Flunitrazepam, Urine
Flunitrazepam belongs to the class of drugs known as Benzodiazepines. The benzodiazepines are a class of medications (drugs) that produce the following effects: sedation and anxiety relief. They are one of the most widely prescribed drugs in the world. Benzodiazepines have essentially replaced the use of barbiturates as the major class of CNS-depressants.
Flunitrazepam is illegal in the United States; however it is approved for use in several countries. It is an intermediate-acting benzodiazepine and is primarily used to treat anxiety and depression. Flunitrazepam can also be used in the management of insomnia, as a sedative, as a muscle-relaxing agent, and it is used as an anticonvulsant. The properties and therapeutic effect of flunitrazepam is 7-10 times stronger than Valium (diazepam). Since the 1950s it has been used illegally to lessen the depression caused by the abuse of stimulants such as cocaine and methamphetamine.
Flunitrazepam is one of the benzodiazepine classes that are typically used by drug abusers. It is known as a “date rape drug” due to the amnesia this drug induces causing the victim to not be able to remember the assault. Long-term abuse can lead to respiratory depression or, in severe cases, coma. Benzodiazepines are frequently abused drugs and associated especially with heroin and cocaine abusers. Benzodiazepines are only legally available through prescription. Many abusers obtain their supply of these drugs by acquiring several prescriptions from several different physicians, or by forging prescriptions, or by obtaining them illicitly.
Alprazolam and diazepam are the two most frequently encountered benzodiazepines on the illicit market today. Benzodiazepines are rapidly metabolized and excreted into the urine, allowing detection by various analytical methods such as Gas Chromatography/Mass Spectroscopy (GC/MS), Liquid Chromatography/Mass Spectroscopy (LC/MS), Immunoassay (IA) screening, and screening spot testing.
Benzodiazepines can elicit the following side effects: amnesia, hostility, irritability, skin rash, allergic reactions, and vivid or disturbing dreams. Overdose effects include shallow respiration, clammy skin, dilated pupils, incoordination, slow speech, impaired thinking, weak and rapid pulse, coma, and possible death.
- Therapeutic monitoring
- Drug abuse evaluation
- Patient Compliance
Therapeutic concentration: 5 - 15 ng/mL
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as IA, or a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.
Urine
Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.
Stability
- Ambient: 5 days
- Refrigeration: 7 days
- Frozen: 30 days
- J Addict Dis. 2010 Oct;29(4):436-48. [PMID: 20924879]
- Ann Clin Biochem. 1997 Sep;34 (Pt 5):460-510. [PMID: 9293303]
- Cochrane Database Syst Rev. 2012 Jul 11;7:CD007139. [PMID: 22786504]
- Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
- Principles of Forensic Toxicology, Fourth Edition. Ed., Barry Levine. AACC Press, Washington DC, Chapter 14, Benzodiazepines, pp. 237-251 (2013).
- Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, Eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill Co. (1996).
- Baselt RC, Ed. Disposition of Toxic Drugs and Chemicals in Man, 6th ed. Foster City, CA: Biomedical Publications, (2002).
- Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7): 169-79
- Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology 1989;11(4): 7-20.
- Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6
- Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs. 1994 July;48(1):25-40.